Junling Li, Huaiyu Zheng, Jenna Olson, Jonathan M Warawa, Chin K Ng
{"title":"利用 18F-Fluorodeoxysorbitol/PET 对抗生素治疗小鼠的应答者和非应答者进行区分。","authors":"Junling Li, Huaiyu Zheng, Jenna Olson, Jonathan M Warawa, Chin K Ng","doi":"10.1007/s11307-024-01957-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Bacterial infection causes significant mortality and morbidity worldwide despite the availability of antibiotics. Differentiation between responders and non-responders early on during antibiotic treatment will be informative to patients and healthcare providers. Our objective was to investigate whether PET imaging with <sup>18</sup>F-Fluorodeoxysorbitol (<sup>18</sup>F-FDS) or <sup>18</sup>F-FDG can be used to differentiate responders from non-responders to antibiotic treatment.</p><p><strong>Procedures: </strong>NTUH-K2044 was used for infection in Albino C57 female mice. Each mouse was inoculated intratracheally with NTUH-K2044 to induce lung infection (n = 8). For treatment studies, two bacterial doses for animal inoculation and two treatment starting times were compared to optimize treatment profiles. <sup>18</sup>F-FDS or <sup>8</sup>F-FDG /PET imaging was performed to monitor treatment progression.</p><p><strong>Results: </strong>Our results demonstrated that the treatment profiles for mice infected with 25 CFU hvKp and antibiotic treatment starting at 24 p.i. were not ideal due to no evidence of lung infection and lack of treatment efficacy. The optimal scheme is to use 250 CUF for infection and start antibiotic treatment at 24 h p.i. to monitor antimicrobial efficacy. 75% of the mice were classified as responders to antibiotic treatment. 25% of the mice were classified as non-responders. <sup>18</sup>F-FDG was used to compare with <sup>18</sup>F-FDS, but all mice showed increased lung uptake of <sup>18</sup>F-FDG during 3-day treatments.</p><p><strong>Conclusions: </strong><sup>18</sup>F-FDS is a promising PET tracer to image bacterial infection. It can be used to monitor response to treatment, and differentiate responders from non-responders to antibiotic treatment, but <sup>18</sup>F-FDG cannot, probably due to the presence of high degree of inflammation before and after treatment.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Differentiation Between Responders and Non-Responders to Antibiotic Treatment in Mice Using <sup>18</sup>F-Fluorodeoxysorbitol/PET.\",\"authors\":\"Junling Li, Huaiyu Zheng, Jenna Olson, Jonathan M Warawa, Chin K Ng\",\"doi\":\"10.1007/s11307-024-01957-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Bacterial infection causes significant mortality and morbidity worldwide despite the availability of antibiotics. Differentiation between responders and non-responders early on during antibiotic treatment will be informative to patients and healthcare providers. Our objective was to investigate whether PET imaging with <sup>18</sup>F-Fluorodeoxysorbitol (<sup>18</sup>F-FDS) or <sup>18</sup>F-FDG can be used to differentiate responders from non-responders to antibiotic treatment.</p><p><strong>Procedures: </strong>NTUH-K2044 was used for infection in Albino C57 female mice. Each mouse was inoculated intratracheally with NTUH-K2044 to induce lung infection (n = 8). For treatment studies, two bacterial doses for animal inoculation and two treatment starting times were compared to optimize treatment profiles. <sup>18</sup>F-FDS or <sup>8</sup>F-FDG /PET imaging was performed to monitor treatment progression.</p><p><strong>Results: </strong>Our results demonstrated that the treatment profiles for mice infected with 25 CFU hvKp and antibiotic treatment starting at 24 p.i. were not ideal due to no evidence of lung infection and lack of treatment efficacy. The optimal scheme is to use 250 CUF for infection and start antibiotic treatment at 24 h p.i. to monitor antimicrobial efficacy. 75% of the mice were classified as responders to antibiotic treatment. 25% of the mice were classified as non-responders. <sup>18</sup>F-FDG was used to compare with <sup>18</sup>F-FDS, but all mice showed increased lung uptake of <sup>18</sup>F-FDG during 3-day treatments.</p><p><strong>Conclusions: </strong><sup>18</sup>F-FDS is a promising PET tracer to image bacterial infection. It can be used to monitor response to treatment, and differentiate responders from non-responders to antibiotic treatment, but <sup>18</sup>F-FDG cannot, probably due to the presence of high degree of inflammation before and after treatment.</p>\",\"PeriodicalId\":18760,\"journal\":{\"name\":\"Molecular Imaging and Biology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-10-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular Imaging and Biology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11307-024-01957-3\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11307-024-01957-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
Differentiation Between Responders and Non-Responders to Antibiotic Treatment in Mice Using 18F-Fluorodeoxysorbitol/PET.
Purpose: Bacterial infection causes significant mortality and morbidity worldwide despite the availability of antibiotics. Differentiation between responders and non-responders early on during antibiotic treatment will be informative to patients and healthcare providers. Our objective was to investigate whether PET imaging with 18F-Fluorodeoxysorbitol (18F-FDS) or 18F-FDG can be used to differentiate responders from non-responders to antibiotic treatment.
Procedures: NTUH-K2044 was used for infection in Albino C57 female mice. Each mouse was inoculated intratracheally with NTUH-K2044 to induce lung infection (n = 8). For treatment studies, two bacterial doses for animal inoculation and two treatment starting times were compared to optimize treatment profiles. 18F-FDS or 8F-FDG /PET imaging was performed to monitor treatment progression.
Results: Our results demonstrated that the treatment profiles for mice infected with 25 CFU hvKp and antibiotic treatment starting at 24 p.i. were not ideal due to no evidence of lung infection and lack of treatment efficacy. The optimal scheme is to use 250 CUF for infection and start antibiotic treatment at 24 h p.i. to monitor antimicrobial efficacy. 75% of the mice were classified as responders to antibiotic treatment. 25% of the mice were classified as non-responders. 18F-FDG was used to compare with 18F-FDS, but all mice showed increased lung uptake of 18F-FDG during 3-day treatments.
Conclusions: 18F-FDS is a promising PET tracer to image bacterial infection. It can be used to monitor response to treatment, and differentiate responders from non-responders to antibiotic treatment, but 18F-FDG cannot, probably due to the presence of high degree of inflammation before and after treatment.
期刊介绍：
Molecular Imaging and Biology (MIB) invites original contributions (research articles, review articles, commentaries, etc.) on the utilization of molecular imaging (i.e., nuclear imaging, optical imaging, autoradiography and pathology, MRI, MPI, ultrasound imaging, radiomics/genomics etc.) to investigate questions related to biology and health. The objective of MIB is to provide a forum to the discovery of molecular mechanisms of disease through the use of imaging techniques. We aim to investigate the biological nature of disease in patients and establish new molecular imaging diagnostic and therapy procedures.
Some areas that are covered are:
Preclinical and clinical imaging of macromolecular targets (e.g., genes, receptors, enzymes) involved in significant biological processes.
The design, characterization, and study of new molecular imaging probes and contrast agents for the functional interrogation of macromolecular targets.
Development and evaluation of imaging systems including instrumentation, image reconstruction algorithms, image analysis, and display.
Development of molecular assay approaches leading to quantification of the biological information obtained in molecular imaging.
Study of in vivo animal models of disease for the development of new molecular diagnostics and therapeutics.
Extension of in vitro and in vivo discoveries using disease models, into well designed clinical research investigations.
Clinical molecular imaging involving clinical investigations, clinical trials and medical management or cost-effectiveness studies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
